Few studies have investigated the intratumoral administration of recombinant, soluble, human TRAIL in vivo.[61, 62, 63] A single treatment in vivo pilot study (data not shown) motivated further testing of the FUS+TRAIL therapy on a larger scale, creating the potential for greater differences in tumor burden. The gene discussed is TNFSF10; the disease is neoplasm.